| Dec'19 | Dec'18 | |||||
|---|---|---|---|---|---|---|
Operating expenses: | ||||||
Research and development | ||||||
37,046 | 11,882 | |||||
General and administrative | ||||||
8,605 | 1,896 | |||||
Total operating expenses | ||||||
45,651 | 13,778 | |||||
Loss from operations | ||||||
-45,651 | -13,778 | |||||
Other income (expense): | ||||||
Change in fair value of preferred stock tranche obligation | ||||||
- | 62,150 | |||||
Change in fair value of anti-dilution right liability | ||||||
- | 5,765 | |||||
Other expenses | ||||||
- | 21 | |||||
Total other income, net | ||||||
1,896 | -67,936 | |||||
Net loss | ||||||
-43,755 | -81,714 | |||||
Net unrealizable gain on marketable securities | ||||||
-6 | - | |||||
Comprehensive loss | ||||||
-43,761 | -81,714 | |||||
Accretion of redeemable convertible preferred stock to redemption value | ||||||
- | 520 | |||||
Net loss attributable to common stockholders | ||||||
-43,755 | -82,234 | |||||
Net loss per common share, basic and diluted | ||||||
-2.90 | -795.28 | |||||
Weighted-average number of shares used in computing net loss per common share, basic and diluted | ||||||
15,070 | 103 | |||||